C
ConvaTec
Global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and…
About ConvaTec
Convatec Group is a leading MedTech company specializing in chronic care solutions, including advanced wound care, ostomy care, continence care, and infusion care. Serving a diverse range of clients, from individual patients to healthcare providers, Convatec operates in nearly 100 countries. The company’s business model revolves around the development, manufacturing, and distribution of medical devices and services that improve patient outcomes and reduce the total cost of care. Revenue is generated through the sale of these products and services, which offer clinical and economic benefits such as infection prevention, skin protection, and enhanced patient care. Convatec’s commitment to innovation and quality is reflected in its pioneering products, such as the compact catheter for women, which combines gentle, protective cathing with everyday discretion and ease of use. With a workforce of around 10,000 employees, Convatec is united by a promise to be 'forever caring,' ensuring that their solutions meet the evolving needs of patients and healthcare systems worldwide.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1978
- Headquarters
- London, United Kingdom
- Listing
- IPO 2016
- Employees
- 6,272
- Open positions
- 277
- Dealroom signal
- 27.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Infusion
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 5 companies, latest Apr 2023
- Capital deployed
- $64M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SECONDARY✓Other financing | Nov 2025 | $0 | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Oct 2025 | $500M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for ConvaTec is 11K monthly website visits, up 20.9% over the last three months. ConvaTec's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
30 TechnologyLondon, United KingdomInnovative nitric oxide therapies targeting chronic infections and multi-drug resistant diseases
→
BlueWind MedicalHerzliya, IsraelEvelops and markets an innovative wireless neuro-stimulation device for the treatment of peripheral neuropathic pain
$320Mvaluation
RG
Rls GlobalMölndals kommun, Sweden
→
180 MedicalOklahoma City, United StatesUrinary catheters, catheter supplies, and ostomy products
→
AM
AbViser MedicalSalt Lake City, United StatesHealthcare products for critical care and surgical marketplaces
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors5 additional known investors
Avista Healthcare Partners
Nordic Capital
Novo Holdings
Novo Ventures
Torben Blicher Buch
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ConvaTec on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ConvaTec’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.